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Purpose of the study
Determination of HIV-1 coreceptor tropism is a major prerequisite before starting treatment with a CCR5-antagonist.While most
of the patients currently under treatment with maraviroc are probably infected with HIV-1 subtype B viruses, recently published
data show differences in the distribution of coreceptor tropism in different HIV-1 subtypes.
Methods
In a Germany-wide project within the HIV-GRADE society, V3-loop sequences of 2466 isolates were analysed with geno2pheno
for coreceptor tropism using a FPR cut-off of 10%. HIV-1 subtype was determined by using the COMET HIV subtyping tool.
Sequences consisted of at least the V3 loop fragment.The ratio of CCR5 vs CXCR4 tropic viruses was calculated for each subtype.
A normalized mean for all analyzed subtypes was calculated to extrapolate the overall ratio of coreceptor usage distribution.
From this the expected distribution in the particular subtype was calculated and compared to the observed one. Statistical
analysis was performed using the chi2 test.
Summary of Results
Most samples were classified as HIV-1 subtype B (79%, n1952). Other subtypes present in at least 23 samples were A1 (9.5%,
n234), C (4.8%, n118), CRF01_AE (2.2%, n55), G (1.6%, n39), D (1.1%, n27), F (0.9%, n23). The calculated
normalized mean distribution over all subtypes was 71% CCR5- vs. 29% CXCR4-tropic viruses. No significant difference compared
to the mean distribution could be observed for HIV-1 subtypes B (71/29%), C (76/24%) and F (70/30%). Higher rates of CXCR4
tropic virus were detected in subtypes D (52/48%, p0.01) and CRF01_AE (49/51%, p0.001), while in HIV-1 subtypes A1
(22/78%, p0.02) and G (13/87%, p0.02), a higher rate of CCR5-tropic virus was observed.
Conclusions
Our analysis shows a different distribution of CCR5 and CXCR4 tropic virus in some subtypes. In contrast to other publications,
we could not observe a statistically significant difference in subtype C compared to the overall mean distribution, while we could
confirm a higher rate of CXCR4-tropic virus in subtype D, as previously described. Without further data on treatment success of
patients with non-B subtypes under treatment with maraviroc, it remains unclear if subtype-specific differences in the
distribution of tropism are biased by differences in clinical variables before test or if there is a bias in the tropism interpretation
system. In the latter case, individual interpretation cut-offs for different subtypes may be necessary.
Published 11 November 2012
Copyright: – 2012 Obermeier M et al; licensee International AIDS Society. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection
Obermeier M et al. Journal of the International AIDS Society 2012, 15(Suppl 4):18214
http://www.jiasociety.org/index.php/jias/article/view/18214 | http://dx.doi.org/10.7448/IAS.15.6.18214
1